Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Innexus Nutraceuticals is a Dutch biotechnology company specializing in the development and supply of high-quality nutraceutical ingredients, most notably its flagship product, OptiPEA. OptiPEA is a premium, GMP-certified brand of palmitoylethanolamide (PEA), a naturally occurring bioactive lipid known for its anti-inflammatory and analgesic properties. The company utilizes a patented production process in the Netherlands to ensure the purity and sustainability of its PEA, which is sourced from RSPO-certified palmitic acid. Innexus positions OptiPEA as a safe, science-backed alternative to CBD and opioids for managing chronic pain and inflammation. Their products are used globally by supplement manufacturers and researchers in the fields of neurology and pain management. The company is recognized as the only European manufacturer of PEA produced under pharmaceutical-grade GMP conditions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on OptiPEA.